BiotechTube

Eluxadoline + Placebo

Phase 2Recruiting
1 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Irritable Bowel Syndrome

Conditions

Irritable Bowel Syndrome

Trial Timeline

Nov 15, 2017 → Dec 1, 2026

NCT ID
NCT03339128

About Eluxadoline + Placebo

Eluxadoline + Placebo is a phase 2 stage product being developed by AbbVie for Irritable Bowel Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03339128. Target conditions include Irritable Bowel Syndrome.

What happened to similar drugs?

7 of 20 similar drugs in Irritable Bowel Syndrome were approved

Approved (7) Terminated (1) Active (13)
✅Ramosetron + PlaceboAstellas PharmaApproved
✅Ramosetron + PlaceboAstellas PharmaApproved
✅duloxetineEli LillyApproved
✅Bacillus clausii + MetronidazoleSanofiApproved
✅Iberogast® and Iberogast® NBayerApproved
✅LinaclotideIronwood PharmaceuticalsApproved
✅Linaclotide + PlaceboIronwood PharmaceuticalsApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03339128Phase 2Recruiting

Competing Products

20 competing products in Irritable Bowel Syndrome

See all competitors
ProductCompanyStageHype Score
linaclotide + placeboAstellas PharmaPhase 2
35
YM060 + PlaceboAstellas PharmaPhase 3
40
Ramosetron + PlaceboAstellas PharmaApproved
43
Ramosetron + PlaceboAstellas PharmaApproved
43
YM060Astellas PharmaPhase 3
40
YM060 + placeboAstellas PharmaPhase 2
35
YM060Astellas PharmaPhase 3
40
linaclotide + PlaceboAstellas PharmaPhase 3
40
RamosetronAstellas PharmaPre-clinical
26
YM060Astellas PharmaPhase 2
35
ONO-2952 + Placebo comparatorOno PharmaceuticalPhase 2
27
ONO-2952 + ONO-2952 Matching PlaceboOno PharmaceuticalPhase 2
35
duloxetineEli LillyApproved
43
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)AbbViePhase 3
40
25mg Eluxadoline + 100mg EluxadolineAbbViePhase 3
47
Placebo + LinaclotideAstraZenecaPhase 3
40
TegaserodNovartisPre-clinical
26
DNK333NovartisPhase 2
35
SMS995 + PlaceboNovartisPhase 1
29
DNK333 + PlaceboNovartisPhase 2
35